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BCR-ABL1 kinase is leukemogenic only when expressed in a HSC with self-renewal capacity, thereby inducing LSC. LSCs are capable of generating large numbers of LPCs: leukemia common myeloid (LCMPs) and leukemia granulocyte/macrophage (LGMPs) progenitors, which cannot self-renew and eventually differentiate to mature elements. In CML blast phase leukemia progenitors (LCMP and LGMP) also display the ability to selfrenew and to sustain leukemogenesis; therefore they are LSC candidates.
CML cells display the signature of genomic instability. 2 The resistance of CML cells to tyrosine kinase inhibitors (TKIs) such as imatinib is often caused by point mutations in the BCR-ABL1 kinase domain, which may emerge under TKI therapy. 3 Generation of the second and third generation of TKIs (dasatinib, nilotinib and ponatinib) to overcome TKI resistance may result in appearance of novel mutations, including compound mutations (polymutants). 4 We reported that TKI-naive and TKI-treated LSCs and LPCs accumulate high levels of ROS and oxidative DNA damage, producing mutations in BCR-ABL1 kinase causing TKI resistance. 5, 6 There are several possible explanations for persistent elevated levels of ROS and oxidative DNA damage in CML-CP cells surviving TKI treatment. For example, the effect of TKIs on BCR-ABL1 kinase-induced signaling pathways stimulating ROS production may be obscured by growth factors, usually resulting in incomplete inhibition or even stimulation of STAT5, AKT, RAC2 and MAPK. 7, 8 Therefore, instead of developing novel inhibitors to target the elusive BCR-ABL1 kinase, drugs downregulating ROS production should be combined with existing TKIs to prevent mutations and to cause more radical elimination of CML-CP cells.
Phosphatidylinositol 3-kinase (PI3K) kinase-mTOR signaling has been implicated in production of ROS in BCR-ABL1-positive cell lines. 9 Recently we showed that RAC2, a putative downstream effector of PI3K, can alter the electron flow through mitochondrial respiratory chain complex III to elevate ROS in LSCs and LPCs. 8 Here we evaluated the role of AKT serine/threonine kinase, another PI3K downstream effector, in generation of ROS-induced oxidative DNA damage and TKI resistance in LSCs and LPCs.
As described before, AKT and RAC2 were inhibited in BCR-ABL1-positive 32Dcl3 cells by expression of specific dominant-negative mutants AKT(K179M) and RAC(T17N), 8, 10 respectively, and in Lin − CD34 + CML-CP cells by AKT activation inhibitor perifosine 11 and RAC inhibitor NSC23766, respectively (Figure 1a) . Inhibition of AKT did not affect the activity of RAC and inhibition of RAC did not affect AKT activity, clearly indicating that their activation status does not depend on each other.
In the presence of growth factors, AKT(K179M) mutant and perifosine diminished ROS levels in annexin V-negative living BCR-ABL1-positive 32Dcl3 cells and Lin − CD34 + cells, respectively (Figures 1b and c) . Perifosine effectively downregulated ROS in Lin − CD34 + CML-CP cells in the G0/G1, S and G2/M cell cycle phases (Figure 1d) , which was associated with reduction of oxidative DNA lesions, 8-oxoG and DSBs (Figures 1e and f) . Finally, inhibition of AKT either by AKT (K179M) mutant or by perifosine resulted in reduction of accumulation of TKIR clones in BCR-ABL1-positive 32Dcl3 cells (Figures 1g and h) .
To determine if AKT is responsible for overproduction of ROS in imatinib-treated LSCs and LPCs, Lin −
CD34
+ CML-CP cells were incubated with imatinib in the presence of growth factors, and ABL1 and AKT activation and ROS levels were measured. Despite inhibition of ABL1 kinase activity, AKT activation was mostly preserved in imatinib-treated Lin − CD34 + cells (Figure 2a ), in concordance with other report. 7 As expected from previous studies with PI3K inhibitors LY294002 or wortmannin and BCR-ABL1 kinase inhibitor imatinib, 13 targeting AKT, a downstream effector of PI3K, with perifosine enhanced the inhibitory effect of imatinib on clonogenic growth of Lin −
+ CML-CP cells (Supplementary Figure 1) . This effect may depend on perifosine-mediated elevation of ROS (including mitochondrial ROS) in a subpopulation of annexin V-positive leukemia cells committed to apoptosis (Supplementary Figure 2) , in concordance with another report.
14 Figure 1 . RAC-independent AKT-induced ROS caused oxidative DNA damage, resulting in accumulation of imatinib-resistant clones. (a) BCR-ABL1-transformed 32Dcl3 cells transfected with AKT(K179M) and Rac(T17N) dominant-negative mutants or empty plasmids (E), 8, 10 and Lin − CD34 + CML-CP cells treated with 10 μM AKT inhibitor perifosine, 25 μM NSC23766 or diluent (C) 8, 11 were tested for activation of AKT and RAC. Western analyses detect AKT phosphorylated on serine 473 (AKT-pS473) and Rac bound to GTP, as described before; 8, 12 total levels of AKT and RAC were also determined as loading controls. 
+ CML-CP cells were left untreated (black bars) or incubated with 10 μM perifosine (grey bars) in the presence of growth factors. 8 (c) ROS were measured with DCFDA in annexin V-negative cells as described before. 5, 8 (d) ROS were detected by DCFDA in G1, S and G2/M phases, determined by Vybrant DyeCycle Orange live cell staining (Invitrogen/Molecular Probes) as described before. 8 ROS measurements are shown on the left side, and percentages of cells in cell cycle phases are indicated at the bottom. (e) 8-oxoG and (f) γ-H2AX detected by specific immunofluorescence as described before. 8 (g,h) BCR-ABL1-positive 32Dcl3 cells transfected with AKT(K179M) mutant or empty plasmid (g) and untreated (Control) or treated with 1 μM perifosine (h) were cultured for 10 weeks. The frequency of TKI-resistant (TKIR) clones was determined as described before. 8 *Po0.05. 
+ CD38 − LSCs, intrinsic differences between leukemic progenitor and stem cells may contribute to the selective AKT effect in LPCs. 15 Moreover, it remains to be determined if AKT and RAC employ overlapping or different downstream signaling pathways.
